Glaziou 1993.

Methods	Design: randomized controlled trial Generation of allocation sequence: "randomly allocated" Allocation concealment: unclear Blinding: outcomes assessor Inclusion of randomized participants in the analysis: 100%
Participants	Number: 44 enrolled (aged 5 to 56 years, mean 17.5 years; 23 males, 21 females) Inclusion criteria: clinically diagnosed scabies defined as the association of pruritus with at least 1 classical burrow Exclusion criteria: other disease; pregnancy; abnormal physical examination (except for cutaneous lesions); abnormal laboratory screen; refused consent
Interventions	1. Oral ivermectin 100 µg/kg bodyweight single dose (23 participants) 2. 10% benzyl benzoate applied to entire body except head on 3 occasions 12 h apart (21 participants)
Outcomes	1. Number of participants clinically cured at 30 days (defined as complete disappearance of initial lesions and pruritus) 2. Adverse events Not included in this review: 3. Number of participants clinically cured at 7 days 4. Number of participants clinically cured at 14 days 5. Mean clinical score (based on number and activity of lesions)
Notes	Location: French Polynesia Date: 1992 All household contacts treated at same time as the participant with 10% benzyl benzoate Merck Sharp and Dohme supplied the ivermectin tablets at no cost